Literature DB >> 18061215

Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background.

Judith A Siuciak1, Sheryl A McCarthy, Douglas S Chapin, Ashley N Martin, John F Harms, Christopher J Schmidt.   

Abstract

The phenotype of genetically modified animals is strongly influenced by both the genetic background of the animal as well as environmental factors. We have previously reported the behavioral and neurochemical characterization of PDE10A knockout mice maintained on a DBA1LacJ (PDE10A(DBA)) genetic background. The aim of the present studies was to assess the behavioral and neurochemical phenotype of PDE10A knockout mice on an alternative congenic C57BL/6N (PDE10A(C57)) genetic background. Consistent with our previous results, PDE10A(C57) knockout mice showed a decrease in exploratory locomotor activity and a delay in the acquisition of conditioned avoidance responding. Also consistent with previous studies, the elimination of PDE10A did not alter basal levels of striatal cGMP or cAMP or affect behavior in several other well-characterized behavioral assays. PDE10A(C57) knockout mice showed a blunted response to MK-801, although to a lesser degree than previously observed in the PDE10A(DBA) knockout mice, and no differences were observed following a PCP challenge. PDE10A(C57) knockout mice showed a significant change in striatal dopamine turnover, which was accompanied by an enhanced locomotor response to AMPH, These studies demonstrate that while many of the behavioral effects of the PDE10A gene deletion appear to be independent of genetic background, the impact of the deletion on behavior can vary in magnitude. Furthermore, the effects on the dopaminergic system appear to be background-dependent, with significant effects observed only in knockout mice on the C57BL6N genetic background.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18061215     DOI: 10.1016/j.neuropharm.2007.10.009

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  14 in total

1.  Stress history increases alcohol intake in relapse: relation to phosphodiesterase 10A.

Authors:  Marian L Logrip; Eric P Zorrilla
Journal:  Addict Biol       Date:  2012-06-28       Impact factor: 4.280

Review 2.  Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease.

Authors:  Katarzyna Urszula Domek-Łopacińska; Joanna B Strosznajder
Journal:  Mol Neurobiol       Date:  2010-03-09       Impact factor: 5.590

3.  A Novel Role of Cyclic Nucleotide Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction.

Authors:  Si Chen; Yishuai Zhang; Janet K Lighthouse; Deanne M Mickelsen; Jiangbin Wu; Peng Yao; Eric M Small; Chen Yan
Journal:  Circulation       Date:  2019-12-05       Impact factor: 29.690

Review 4.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications.

Authors:  Subramaniam Uthayathas; Gunasingh J Masilamoni; Christopher L Shaffer; Christopher J Schmidt; Frank S Menniti; Stella M Papa
Journal:  Neuropharmacology       Date:  2014-02       Impact factor: 5.250

6.  Sex differences in the long-term effects of past stress on alcohol self-administration, glucocorticoid sensitivity and phosphodiesterase 10A expression.

Authors:  Marian L Logrip; Sean C Gainey
Journal:  Neuropharmacology       Date:  2019-11-19       Impact factor: 5.250

7.  cGMP Signaling, Phosphodiesterases and Major Depressive Disorder.

Authors:  Gillian W Reierson; Shuyu Guo; Claudio Mastronardi; Julio Licinio; Ma-Li Wong
Journal:  Curr Neuropharmacol       Date:  2011-12       Impact factor: 7.363

8.  Validation of simple sequence length polymorphism regions of commonly used mouse strains for marker assisted speed congenics screening.

Authors:  Channabasavaiah B Gurumurthy; Poonam S Joshi; Scott G Kurz; Masato Ohtsuka; Rolen M Quadros; Donald W Harms; K C Kent Lloyd
Journal:  Int J Genomics       Date:  2015-02-28       Impact factor: 2.326

Review 9.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

10.  Radiosynthesis and Radiotracer Properties of a 7-(2-[18F]Fluoroethoxy)-6-methoxypyrrolidinylquinazoline for Imaging of Phosphodiesterase 10A with PET.

Authors:  Uta Funke; Winnie Deuther-Conrad; Gregor Schwan; Aurélie Maisonial; Matthias Scheunemann; Steffen Fischer; Achim Hiller; Detlef Briel; Peter Brust
Journal:  Pharmaceuticals (Basel)       Date:  2012-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.